Traders should monitor the March 28 presentation for topline efficacy and safety data; positive results could trigger substantial upside given the lack of approved PG therapies and InflaRx's small market cap. Consider positioning ahead of this binary event, with risk managed against potential underwhelming outcomes.
Price Chart
Executive Summary
InflaRx N.V. announced that Phase 3 data for its drug vilobelimab in pyoderma gangrenosum (PG) will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This late-breaking oral presentation represents a key clinical milestone and will provide the first public readout of pivotal trial results in a rare inflammatory skin disease with no approved therapies.
Key Facts
- Phase 3 trial results for vilobelimab in ulcerative pyoderma gangrenosum will be presented at AAD 2026 in a late-breaking oral session.
- Presentation scheduled for March 28, 2026, 2:24-2:36 PM MT by Dr. Benjamin Kaffenberger.
- Vilobelimab is a first-in-class anti-C5a monoclonal antibody with prior positive data in other inflammatory conditions.
- No efficacy or safety data are disclosed in the press release, but late-breaking status suggests potentially significant findings.
- PG is an orphan indication with no FDA-approved treatments, meaning positive data could support accelerated approval and commercialization.
Financial Impact
Potential near-term value inflection for a $54M market cap company; successful Phase 3 data could justify significant revenue potential in a high unmet need indication.
Risk Factors
- Phase 3 data may not meet primary endpoints or show safety concerns.
- Late-breaking selection does not guarantee positive results — it only indicates clinical importance.
- Commercial success depends on pricing, access, and physician adoption in a rare disease setting.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258056 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $1.56 | awaiting T+20 | — | $1.58 (+0.96%) |
Oct 22, 2026 4d ago | Press Release | $1.53 | awaiting T+20 | — | $1.58 (+2.94%) |
Oct 2, 2026 25d ago | Press Release | $1.72 | awaiting T+20 | — | $1.58 (−8.43%) |
Oct 1, 2026 26d ago | Press Release | $1.71 | awaiting T+20 | — | $1.58 (−7.89%) |
Aug 14, 2026 10w ago | 424B5 | $2.07 $2.02 | ▲ +2.42% | ▲ +0.44% | $1.58 (+23.91%) |
Aug 13, 2026 10w ago | EFFECT | $2.01 $2.09 | ▼ −3.98% | ▼ −5.73% | $1.58 (+21.64%) |
Aug 6, 2026 11w ago | 6-K | $1.72 $2.23 | ▲ +29.65% | ▲ +29.05% | $1.58 (−8.43%) |
Jun 30, 2026 16w ago | 6-K | $2.33 $1.65 | ▼ −29.18% | ▼ −27.00% | $1.58 (−32.40%) |
Jun 30, 2026 17w ago | Press Release | $2.24 $1.70 | ▼ −24.11% | ▼ −23.08% | $1.58 (−29.69%) |
May 6, 2026 24w ago | 424B5 | $2.65 $2.06 | ▲ +22.26% | ▲ +25.40% | $1.58 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers